CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $2.65B, above the global median of $1.15B
- PositionReturn on equity is -157.2%, lower than 95% of its Biotechnology peers (median -24.5%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
17.82BCNY2.65B · vs all stocks (USD)
Revenue (TTM)
1.36BCNY202.78M · vs all stocks (USD)
Profit Margin
-58.98%vs Biotechnology peers
Beta
0.7250xvs all stocks
52-Week Change
-44.33%vs all stocks
Market Capitalization
17.82BCNY2.65B · vs all stocks (USD)
Enterprise Value
19.14BCNY2.85B · vs all stocks (USD)
Forward P/E
25.09xvs Biotechnology peers
Price to Sales (TTM)
12.89xvs Biotechnology peers
Price to Book (MRQ)
20.74xvs Biotechnology peers
Enterprise to Revenue
14.04xvs Biotechnology peers
Enterprise to EBITDA
-38.92xvs Biotechnology peers
Gross Margin
89.57%vs Biotechnology peers
Profit Margin
-58.98%vs Biotechnology peers
Operating Margin
-36.65%vs Biotechnology peers
Return on Assets (TTM)
-9.82%vs Biotechnology peers
Return on Equity (TTM)
-157.16%vs Biotechnology peers
Revenue (TTM)
1.36BCNY202.78M · vs all stocks (USD)
Revenue per Share (TTM)
3.31CNYUpdated Aug 21, 2026Quarterly Revenue Growth
-37.80%vs Biotechnology peers
Gross Profit (TTM)
1.22BCNY181.73M · vs all stocks (USD)
EBITDA (TTM)
-491.91MCNY-73.15M · vs all stocks (USD)
Net Income (TTM)
-804.31MCNY-119.61M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-43.86%vs Biotechnology peers
Operating Cash Flow (TTM)
-261.57MCNY-38.90M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-232.93MCNY-34.64M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.00CNYUpdated Aug 21, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Minority Interest (Equity)
-7.94MCNYFY2025 · Dec 31, 2025Revenue
1.56BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
107.68MCNYFY2025 · Dec 31, 2025Gross Profit
1.45BCNYFY2025 · Dec 31, 2025Operating Income
-337.49MCNY-50.19M · vs all stocks (USD)
Pre-tax Income
-563.62MCNYFY2025 · Dec 31, 2025Income Tax Expense
2.58MCNYFY2025 · Dec 31, 2025Net Income
-566.20MCNYFY2025 · Dec 31, 2025EBIT
-479.79MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-286.05MCNYFY2025 · Dec 31, 2025Research & Development
837.85MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
625.15MCNYFY2025 · Dec 31, 2025Other Operating Expenses
15.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
1.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
83.83MCNYFY2025 · Dec 31, 2025EPS (Basic)
-1.32CNYFY2025 · Dec 31, 2025EPS (Diluted)
-1.32CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
427.92MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
427.92MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-566.20MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
1.35MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-369.14MCNYFY2025 · Dec 31, 2025Free Cash Flow
-585.66MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
770.33MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-566.20MCNYFY2025 · Dec 31, 2025Other Non-cash Items
103.61MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
174.26MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-80.80MCNYFY2025 · Dec 31, 2025Capital Expenditures
-216.52MCNYFY2025 · Dec 31, 2025Purchase of Investments
-1.77BCNYFY2025 · Dec 31, 2025Sale of Investments
1.69BCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-291.98MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.39BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.79BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-111.83MCNYFY2025 · Dec 31, 2025Other Financing Charges
537.82MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
1.02BCNYFY2025 · Dec 31, 2025Shares Outstanding
470.34MSharesUpdated Aug 21, 2026Float Shares
98.56MSharesUpdated Aug 21, 2026% Held by Insiders
73.45%vs all stocks
% Held by Institutions
3.30%vs all stocks
Total Cash (MRQ)
1.56BCNY232.26M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.32CNYUpdated Aug 21, 2026Total Debt (MRQ)
3.14BCNY466.78M · vs all stocks (USD)
Total Debt to Equity (MRQ)
3.76xvs Biotechnology peers
Current Ratio (MRQ)
0.9800xvs Biotechnology peers
Book Value per Share (MRQ)
1.80CNYUpdated Aug 21, 2026Total Assets
3.82BCNY568.71M · vs all stocks (USD)
Total Current Assets
1.90BCNYFY2025 · Dec 31, 2025Total Liabilities
3.70BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.93BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
968.86MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.74BCNYFY2025 · Dec 31, 2025Cash
770.33MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
770.33MCNYFY2025 · Dec 31, 2025Other Short-term Investments
88.29MCNYFY2025 · Dec 31, 2025Accounts Receivable
540.99MCNYFY2025 · Dec 31, 2025Inventory
336.36MCNYFY2025 · Dec 31, 2025Accounts Payable
130.25MCNYFY2025 · Dec 31, 2025Short-term Debt
2.29BCNYFY2025 · Dec 31, 2025Long-term Debt
845.98MCNYFY2025 · Dec 31, 2025Common Stock (Book)
445.34MCNYFY2025 · Dec 31, 2025Retained Earnings
-4.41BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
120.33MCNY17.89M · vs all stocks (USD)
52-Week Low
31.35CNYUpdated Aug 21, 202652-Week High
70.50CNYUpdated Aug 21, 202652-Week Change
-44.33%vs all stocks
Beta
0.7250xvs all stocks
50-Day MA
35.90CNYUpdated Aug 21, 2026200-Day MA
41.04CNYUpdated Aug 21, 2026Avg 10-Day Volume
3.97MSharesUpdated Aug 21, 2026Avg 30-Day Volume
3.47MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-1.86CNYUpdated Aug 21, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Return on equity is -157.2%, lower than 95% of its Biotechnology peers (median -24.5%)Significant
Return on equity: -1.57Industry median: -0.25Industry P5: -1.55Peers compared: 197
Debt-to-equity is 3.76×, higher than 95% of its Biotechnology peers (median 0.1×)Significant
Debt-to-equity: 3.76Industry median: 0.10Industry P95: 2.96Peers compared: 197
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.90Profit Margin: -0.59
Financial Health
Altman Z-Score 1: distress zoneCritical
Altman Z-Score: 1.00
High structural barrier to entryNotable
Barrier to Entry: 4.17
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $2.65B, above the global median of $1.15BNotable
Market cap (USD): 2,650,163,914.388Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
AtaiBeckley Inc.
Tier 1ProductionApproval-Gated PipelineRule
MicroPort Scientific Corporation
Tier 1ProductionApproval-Gated PipelineRule
Kodiak Sciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Maravai Lifesciences Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tarsus Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Ligachem Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Trevi Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sellas Life Sciences Group Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Establishment Labs Holdings Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Double Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule